These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 18041674)

  • 21. Development and application of Hsp90 inhibitors.
    Solit DB; Chiosis G
    Drug Discov Today; 2008 Jan; 13(1-2):38-43. PubMed ID: 18190862
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EORTC-NCI-AACR--20th symposium molecular targets and cancer therapeutics.
    Din S
    IDrugs; 2008 Dec; 11(12):855-6. PubMed ID: 19051141
    [No Abstract]   [Full Text] [Related]  

  • 23. Drugging the cancer kinome: progress and challenges in developing personalized molecular cancer therapeutics.
    Workman P
    Cold Spring Harb Symp Quant Biol; 2005; 70():499-515. PubMed ID: 16869789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rational combinations using HDAC inhibitors.
    Bots M; Johnstone RW
    Clin Cancer Res; 2009 Jun; 15(12):3970-7. PubMed ID: 19509171
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tanespimycin: the opportunities and challenges of targeting heat shock protein 90.
    Erlichman C
    Expert Opin Investig Drugs; 2009 Jun; 18(6):861-8. PubMed ID: 19466875
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Screening for the drug-seeds of antitumor agents].
    Fujimaki T; Imoto M
    Nihon Rinsho; 2012 Nov; 70 Suppl 8():303-7. PubMed ID: 23513856
    [No Abstract]   [Full Text] [Related]  

  • 27. EORTC-NCI-AACR--14th Symposium. Molecular targets and cancer therapeutics--part II. 19-22 November 2002, Frankfurt, Germany.
    Patterson C
    IDrugs; 2003 Jan; 6(1):27-9. PubMed ID: 12838969
    [No Abstract]   [Full Text] [Related]  

  • 28. Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase.
    Budillon A; Bruzzese F; Di Gennaro E; Caraglia M
    Curr Drug Targets; 2005 May; 6(3):337-51. PubMed ID: 15857292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Biological diversity of protein lysine acetylation which has been revealed by small molecule inhibitors].
    Shimazu T; Horinouchi S; Yoshida M
    Tanpakushitsu Kakusan Koso; 2007 Oct; 52(13 Suppl):1751-7. PubMed ID: 18051411
    [No Abstract]   [Full Text] [Related]  

  • 30. AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. 14-18th November 2005, Philadelphia, PA, USA.
    Veryard C
    IDrugs; 2006 Jan; 9(1):1-3. PubMed ID: 16374720
    [No Abstract]   [Full Text] [Related]  

  • 31. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors.
    Prince HM; Bishton MJ; Johnstone RW
    Future Oncol; 2009 Jun; 5(5):601-12. PubMed ID: 19519200
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy.
    Carew JS; Giles FJ; Nawrocki ST
    Cancer Lett; 2008 Sep; 269(1):7-17. PubMed ID: 18462867
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Poly adenosine diphosphate-ribose polymerase inhibitors and heat shock protein 90 inhibitors.
    Riely GJ
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1803-4. PubMed ID: 22005537
    [No Abstract]   [Full Text] [Related]  

  • 34. Beyond monoclonal antibodies: new therapeutic agents in non-Hodgkin's lymphomas.
    Delmonte A; Ghielmini M; Sessa C
    Oncologist; 2009 May; 14(5):511-25. PubMed ID: 19411316
    [TBL] [Abstract][Full Text] [Related]  

  • 35. AACR-NCI-EORTC--17th Symposium: Molecular Targets and Cancer Therapeutics.
    Garvey R
    IDrugs; 2006 Feb; 9(2):90-2. PubMed ID: 16523394
    [No Abstract]   [Full Text] [Related]  

  • 36. Heat-shock protein 90 (Hsp90) as a molecular target for therapy of gastrointestinal cancer.
    Moser C; Lang SA; Stoeltzing O
    Anticancer Res; 2009 Jun; 29(6):2031-42. PubMed ID: 19528462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EORTC-NCI-AACR--14th Symposium. Molecular targets and cancer therapeutics--part I. 19-22 November 2002, Frankfurt, Germany.
    Patterson C
    IDrugs; 2003 Jan; 6(1):23-6. PubMed ID: 12838967
    [No Abstract]   [Full Text] [Related]  

  • 38. 3rd EORTC-NCI International Meeting on Cancer Molecular Markers: From Discovery to Clinical Practice.
    Taube SE; Gion M; Schilsky RL
    Expert Rev Mol Diagn; 2004 Jul; 4(4):431-3. PubMed ID: 15225090
    [No Abstract]   [Full Text] [Related]  

  • 39. Development of vorinostat: current applications and future perspectives for cancer therapy.
    Richon VM; Garcia-Vargas J; Hardwick JS
    Cancer Lett; 2009 Aug; 280(2):201-10. PubMed ID: 19181442
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AACR-NCI-EORTC--17th symposium: Molecular targets and cancer therapeutics. Drug highlights. 14-18th November 2005, Philadelphia, PA, USA.
    Garvey R
    IDrugs; 2006 Jan; 9(1):9-12. PubMed ID: 16374723
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.